JP2019508063A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508063A5
JP2019508063A5 JP2018559162A JP2018559162A JP2019508063A5 JP 2019508063 A5 JP2019508063 A5 JP 2019508063A5 JP 2018559162 A JP2018559162 A JP 2018559162A JP 2018559162 A JP2018559162 A JP 2018559162A JP 2019508063 A5 JP2019508063 A5 JP 2019508063A5
Authority
JP
Japan
Prior art keywords
mir
cancer
item
recombinant hsv
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015417 external-priority patent/WO2017132552A1/en
Publication of JP2019508063A publication Critical patent/JP2019508063A/ja
Publication of JP2019508063A5 publication Critical patent/JP2019508063A5/ja
Priority to JP2021089151A priority Critical patent/JP7174109B2/ja
Priority to JP2022177413A priority patent/JP2023001236A/ja
Priority to JP2024028567A priority patent/JP2024052881A/ja
Pending legal-status Critical Current

Links

JP2018559162A 2016-01-27 2017-01-27 腫瘍溶解性ウイルスベクター及びその使用 Pending JP2019508063A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021089151A JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用
JP2022177413A JP2023001236A (ja) 2016-01-27 2022-11-04 腫瘍溶解性ウイルスベクター及びその使用
JP2024028567A JP2024052881A (ja) 2016-01-27 2024-02-28 腫瘍溶解性ウイルスベクター及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287619P 2016-01-27 2016-01-27
US62/287,619 2016-01-27
PCT/US2017/015417 WO2017132552A1 (en) 2016-01-27 2017-01-27 Oncolytic viral vectors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021089151A Division JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用

Publications (2)

Publication Number Publication Date
JP2019508063A JP2019508063A (ja) 2019-03-28
JP2019508063A5 true JP2019508063A5 (enExample) 2020-06-18

Family

ID=57995301

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018559162A Pending JP2019508063A (ja) 2016-01-27 2017-01-27 腫瘍溶解性ウイルスベクター及びその使用
JP2021089151A Active JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用
JP2022177413A Withdrawn JP2023001236A (ja) 2016-01-27 2022-11-04 腫瘍溶解性ウイルスベクター及びその使用
JP2024028567A Pending JP2024052881A (ja) 2016-01-27 2024-02-28 腫瘍溶解性ウイルスベクター及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021089151A Active JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用
JP2022177413A Withdrawn JP2023001236A (ja) 2016-01-27 2022-11-04 腫瘍溶解性ウイルスベクター及びその使用
JP2024028567A Pending JP2024052881A (ja) 2016-01-27 2024-02-28 腫瘍溶解性ウイルスベクター及びその使用

Country Status (18)

Country Link
US (3) US10391132B2 (enExample)
EP (2) EP3408382B1 (enExample)
JP (4) JP2019508063A (enExample)
KR (1) KR20180136435A (enExample)
CN (2) CN116904404A (enExample)
AR (1) AR107469A1 (enExample)
AU (1) AU2017212713B2 (enExample)
BR (1) BR112018015390A2 (enExample)
CA (1) CA3011933A1 (enExample)
DK (1) DK3408382T3 (enExample)
ES (1) ES2919953T3 (enExample)
IL (2) IL260790B (enExample)
MX (1) MX2018009126A (enExample)
PT (1) PT3408382T (enExample)
RU (2) RU2749050C2 (enExample)
SG (2) SG10202107138TA (enExample)
TW (1) TWI798168B (enExample)
WO (1) WO2017132552A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015390A2 (pt) 2016-01-27 2018-12-18 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US10682425B2 (en) * 2016-12-14 2020-06-16 The Regents Of The University Of California Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
EP3594329A4 (en) * 2017-04-19 2021-02-24 The University Of Tokyo GENETICALLY MODIFIED COXSACKIE VIRUS, AND PHARMACEUTICAL COMPOSITION
CA3059480A1 (en) * 2017-04-28 2018-11-01 Toray Industries, Inc. Kit, device, and method for detecting ovarian tumor
WO2019023483A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
JP2021514190A (ja) * 2018-02-19 2021-06-10 コンバインド セラピューティクス インコーポレイテッドCombined Therapeutics, Inc. コード化リボ核酸の器官保護発現および調節のための組成物および方法
CA3074901A1 (en) 2017-09-11 2019-03-14 Imba - Institut Fur Molekulare Biotechnologie Gmbh Tumor organoid model
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒(oHSV)專性載體及其建構體的建構
CN107723367A (zh) * 2017-10-27 2018-02-23 青岛大学 miRNA‑885‑3p的应用和应用其的产品
CN107674918A (zh) * 2017-11-10 2018-02-09 上海交通大学医学院 has‑mir‑195‑5p作为生物标志物在制备肺癌诊断试剂盒中的应用
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CA3096938A1 (en) 2018-04-10 2019-10-17 Ottawa Hospital Research Institute Microrna-based compositions and methods used in disease treatment
EP3781188A4 (en) * 2018-04-13 2022-03-02 2seventy bio, Inc. ADOPTIVE CELL THERAPY
CN108707625B (zh) * 2018-07-03 2021-09-21 云笛生物科技有限公司 mir-124和HER2-shRNA双基因表达盒病毒载体、构建方法、病毒、应用
CN109091491A (zh) * 2018-08-02 2018-12-28 广州安镝声生物医药科技有限公司 lncRNA H19的靶miRNA miR19a-3p及其应用
CN109091492A (zh) * 2018-08-02 2018-12-28 广州安镝声生物医药科技有限公司 lncRNA H19的靶miRNA miR-106b-5p及其应用
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
TWI690597B (zh) * 2018-11-14 2020-04-11 國立中央大學 泌尿上皮癌的檢測套組及檢測方法
KR20210098483A (ko) * 2018-11-29 2021-08-10 바이로진 바이오테크 캐나다 리미티드 신경독성이 감소된 hsv 벡터
KR20200069259A (ko) * 2018-12-06 2020-06-16 국립암센터 nc886을 포함하는 암살상 바이러스 활성 증진 또는 생산 증진용 조성물
AU2020204989A1 (en) * 2019-01-04 2021-07-08 Elevatebio Technologies, Inc. Encapsulated RNA polynucleotides and methods of use
CN109762903B (zh) * 2019-01-31 2022-02-01 山东大学齐鲁医院 miR-1246和/或TERF2IP在诊治胶质瘤中的应用
US12209250B2 (en) * 2019-03-14 2025-01-28 Massachusetts Institute Of Technology Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof
CN110283794B (zh) * 2019-05-30 2021-04-23 伍泽堂 重组溶瘤病毒以及制备方法、应用和药物
CN112011570B (zh) * 2019-05-31 2023-04-18 北京合生基因科技有限公司 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
JP2022541197A (ja) * 2019-07-16 2022-09-22 ユニヴェルシテ・コート・ダジュール 腫瘍溶解性ウイルスに対する対象の感受性又は抵抗性を評価する方法、組換えウイルス、その調製、及び使用
AU2020326774A1 (en) * 2019-08-05 2022-03-03 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors
CN110468132B (zh) * 2019-08-15 2022-11-25 西南大学 一种sgRNA及转基因表达载体、表达品系、筛选方法
CN110433171B (zh) * 2019-08-20 2022-08-19 中山大学附属第六医院 miRNA-1293在制备抗结直肠肿瘤药物中的应用
US20220380735A1 (en) 2019-10-10 2022-12-01 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
KR102320430B1 (ko) * 2020-01-29 2021-11-03 서울대학교병원 수모세포종에 대한 miR-135b, miR-135a 및 이들의 표적 유전자 AMOTL2의 용도
EP4136241A2 (en) * 2020-04-14 2023-02-22 Eidgenössische Technische Hochschule Zürich Cell classifier circuits and methods of use thereof
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
WO2021244628A1 (zh) * 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
JP7539739B2 (ja) * 2020-07-10 2024-08-26 上海米然生物科技有限公司 蛍光架橋型RNase H突然変異体コンジュゲート、miRNAの組み合わせ及びその使用
CA3187345A1 (en) 2020-07-31 2022-02-17 Romain MICOL Compositions and methods for improved vaccination
CA3197748A1 (en) * 2020-11-13 2022-05-19 Henry Fechner Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas
CN116744951A (zh) * 2020-12-25 2023-09-12 苏州系统医学研究所 一种包含溶瘤病毒的组合物及其在肿瘤治疗中的应用
TW202305123A (zh) * 2021-03-24 2023-02-01 加拿大商復諾健生物科技加拿大有限公司 轉錄及轉譯雙重調節之溶瘤單純疱疹病毒載體
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
US20250049867A1 (en) * 2021-08-31 2025-02-13 Virogin Biotech Canada Ltd. Engineered oncolytic herpesviruses
CN113637761B (zh) * 2021-10-15 2025-01-24 北京百奥思科生物医学技术有限公司 用于黑色素瘤诊断和治疗的miRNA标志物及其相关产品
WO2023142040A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd. Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
CN118634241A (zh) * 2022-06-27 2024-09-13 浙江大学 抗口腔肿瘤药物活性成分及其用途
KR102726438B1 (ko) * 2022-11-29 2024-11-06 주식회사 신렉스 암 세포를 표적으로 하는 복수 개의 miRNA를 발현하도록 유전적 조작된 박테리아 균주
GB2634272A (en) * 2023-10-04 2025-04-09 Averywell Ltd Methods
KR20250051170A (ko) * 2023-10-06 2025-04-17 아주대학교산학협력단 자궁경부암 환자의 조기 사망 예측용 바이오마커
CN119932194A (zh) * 2025-01-23 2025-05-06 上海市第十人民医院 一种用于靶标rna多重分析的共价荧光编码组装体、dna荧光条形码及应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
WO1999006583A1 (en) 1997-07-31 1999-02-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
ATE305510T1 (de) 1997-12-17 2005-10-15 Immunex Corp Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
US20020187126A1 (en) 2001-04-06 2002-12-12 Mount Sinai School Of Medicine Methods for viral oncoapoptosis in cancer therapy
MXPA04003057A (es) 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
GB0406389D0 (en) 2004-03-22 2004-04-21 Istituto Superiore Di Sanito Recombinant herpes simplex virus and uses therefor
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
JP5054522B2 (ja) 2004-08-20 2012-10-24 ヴィラリティクス リミテッド 血液ガンを治療するための方法および組成物
EP1805213B1 (en) 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US20080160031A1 (en) 2005-01-17 2008-07-03 Viralytics Limited Method and Composition for Treatment of Neoplasms
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
DK2341149T3 (en) 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US9428756B2 (en) 2006-08-11 2016-08-30 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
US8586028B2 (en) 2007-05-09 2013-11-19 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
NO2700405T3 (enExample) 2008-05-29 2018-09-01
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
MX337838B (es) 2008-11-07 2016-03-22 Dupont Nutrition Biosci Aps Secuencias de repetidos palindromicos cortos regularmente intercalados agrupados de bifidobacterias.
CA2755245A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
CA2795695A1 (en) 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
EA201390586A1 (ru) 2010-10-20 2014-11-28 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Последовательности crispr-cas lactococcus
JP6158170B2 (ja) 2011-04-27 2017-07-12 アミリス, インコーポレイテッド ゲノム修飾のための方法
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
AU2012322999B2 (en) 2011-10-11 2017-08-10 Universitat Zurich Prorektorat Mnw Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2591796A1 (en) 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013109604A1 (en) * 2012-01-19 2013-07-25 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
SG10201606959PA (en) 2012-02-24 2016-09-29 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
AU2014204015A1 (en) 2013-01-04 2015-07-09 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR102382295B1 (ko) 2013-07-17 2022-04-04 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 효율적인 유전자 전달 적용을 위한 비독성 hsv 벡터 및 이의 생산을 위한 보완 세포
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性hsvベクター
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
US10647964B2 (en) 2015-03-05 2020-05-12 Northwestern University Non-neuroinvasive viruses and uses thereof
US10083137B2 (en) 2015-04-02 2018-09-25 Atmel Corporation Peripheral interface circuit for serial memory
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
BR112018015390A2 (pt) 2016-01-27 2018-12-18 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
EP3380621A4 (en) 2016-04-22 2019-05-08 Immvira Co., Limited CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
JP7200104B2 (ja) 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
CN118436692A (zh) 2016-08-09 2024-08-06 图恩斯通有限合伙公司 表达il12的溶瘤弹状病毒
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2019023483A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2019508063A5 (enExample)
RU2018130673A (ru) Онколитические вирусные векторы и их применение
JP7652823B2 (ja) 腫瘍溶解性ウイルスベクター及びその使用
ES2544713T3 (es) Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
US9821009B2 (en) Method for modulating microRNA content in living beings and the use thereof
EP2865393B1 (en) Compositions comprising mir-143 and/or mir-145 or (an) expression vector(s) thereof, for use as medicaments
JP2008519606A5 (enExample)
JP2015509366A5 (enExample)
JP2015504307A5 (enExample)
CN102218144A (zh) 一种调节生物体内微小核糖核酸含量的方法及其用途
US20250049867A1 (en) Engineered oncolytic herpesviruses
Sheervalilou et al. A review on microRNAs’ function, detection and evaluation methods, expression dysregulation mechanisms and possible applications in clinical phase as diagnostic, prognostic and therapeutic biomarkers of lung cancer patients
Noorali et al. Effec t of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Viru s Genotype 1b Viral Load in Infected Liver Cells
İmir et al. OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ